PolyNovo Requests Trading Halt Ahead of NovoSorb Device Trial Results in Neuroischemic Diabetic Wounds

MT Newswires Live

Sep 12

PolyNovo (ASX:PNV) requested a trading halt for its securities on Friday in respect of a poster made public on the results of a chronic wound investigator-initiated clinical trial comparing the use of NovoSorb biodegradable temporizing matrix device combined with negative pressure wound therapy with the clinical standard-of-care in subjects with neuroischemic diabetic wounds, according to a same-day Australian bourse filing.

NovoSorb is a synthetic, biodegradable device designed to facilitate the growth of skin tissue within a patented polyurethane matrix.

The medical technology company requested the trading halt to remain in place until the release of an announcement or the opening of the market on Sept. 16.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2566294468"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566294468\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566294468?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 11:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566294468","market":"sh","top_or_hot":-1,"title":"PolyNovo Requests Trading Halt Ahead of NovoSorb Device Trial Results in Neuroischemic Diabetic Wounds","media":"MT Newswires Live","content":"<html><body><p> PolyNovo (ASX:PNV) requested a trading halt for its securities on Friday in respect of a poster made public on the results of a chronic wound investigator-initiated clinical trial comparing the use of NovoSorb biodegradable temporizing matrix device combined with negative pressure wound therapy with the clinical standard-of-care in subjects with neuroischemic diabetic wounds, according to a same-day Australian bourse filing.</p><p>NovoSorb is a synthetic, biodegradable device designed to facilitate the growth of skin tissue within a patented polyurethane matrix.</p><p>The medical technology company requested the trading halt to remain in place until the release of an announcement or the opening of the market on Sept. 16.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PolyNovo Requests Trading Halt Ahead of NovoSorb Device Trial Results in Neuroischemic Diabetic Wounds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPolyNovo Requests Trading Halt Ahead of NovoSorb Device Trial Results in Neuroischemic Diabetic Wounds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-12 11:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PolyNovo (ASX:PNV) requested a trading halt for its securities on Friday in respect of a poster made public on the results of a chronic wound investigator-initiated clinical trial comparing the use of NovoSorb biodegradable temporizing matrix device combined with negative pressure wound therapy with the clinical standard-of-care in subjects with neuroischemic diabetic wounds, according to a same-day Australian bourse filing.</p><p>NovoSorb is a synthetic, biodegradable device designed to facilitate the growth of skin tissue within a patented polyurethane matrix.</p><p>The medical technology company requested the trading halt to remain in place until the release of an announcement or the opening of the market on Sept. 16.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7126","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2566294468","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566294468","pubTimestamp":1757646805,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PolyNovo  requested a trading halt for its securities on Friday in respect of a poster made public on the results of a chronic wound investigator-initiated clinical trial comparing the use of NovoSorb biodegradable temporizing matrix device combined with negative pressure wound therapy with the clinical standard-of-care in subjects with neuroischemic diabetic wounds, according to a same-day Australian bourse filing.NovoSorb is a synthetic, biodegradable device designed to facilitate the growth of skin tissue within a patented polyurethane matrix.The medical technology company requested the trading halt to remain in place until the release of an announcement or the opening of the market on Sept. 16.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7126":"医疗保健用品","PNV.AU":"POLYNOVO LTD","BK7508":"医药生物股"},"translate_title":"PolyNovo要求在NovoSorb设备试验结果导致糖尿病神经缺血性伤口之前暂停交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PNV.AU":0.9},"content_text":"PolyNovo (ASX:PNV) requested a trading halt for its securities on Friday in respect of a poster made public on the results of a chronic wound investigator-initiated clinical trial comparing the use of NovoSorb biodegradable temporizing matrix device combined with negative pressure wound therapy with the clinical standard-of-care in subjects with neuroischemic diabetic wounds, according to a same-day Australian bourse filing.NovoSorb is a synthetic, biodegradable device designed to facilitate the growth of skin tissue within a patented polyurethane matrix.The medical technology company requested the trading halt to remain in place until the release of an announcement or the opening of the market on Sept. 16.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}